Orthocell Ltd
ASX:OCC

Watchlist Manager
Orthocell Ltd Logo
Orthocell Ltd
ASX:OCC
Watchlist
Price: 1.28 AUD -2.29%
Market Cap: 306.1m AUD
Have any thoughts about
Orthocell Ltd?
Write Note

Orthocell Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Orthocell Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Orthocell Ltd
ASX:OCC
Capital Expenditures
-AU$942k
CAGR 3-Years
-71%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Mesoblast Ltd
ASX:MSB
Capital Expenditures
-$271k
CAGR 3-Years
45%
CAGR 5-Years
1%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Capital Expenditures
-$1.3B
CAGR 3-Years
9%
CAGR 5-Years
0%
CAGR 10-Years
-12%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Capital Expenditures
-AU$5.6m
CAGR 3-Years
-87%
CAGR 5-Years
-85%
CAGR 10-Years
N/A
Telix Pharmaceuticals Ltd
ASX:TLX
Capital Expenditures
-AU$10.8m
CAGR 3-Years
-222%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Capital Expenditures
-AU$307k
CAGR 3-Years
20%
CAGR 5-Years
8%
CAGR 10-Years
-4%
No Stocks Found

Orthocell Ltd
Glance View

Market Cap
306.1m AUD
Industry
Biotechnology

Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is engaged in the development and commercialization of cell therapies and biological medical devices. The firm offers two main products, including CelGro and Ortho-ATI. CelGro is a naturally derived collagen medical device, which is designed for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons and cartilage. The company represents a paradigm shift in bone and soft tissue reconstruction. Ortho-ATI is a cell therapy for treatment of chronic tendon injuries. The treatment uses patient’s own tendon-derived cells to stimulate tendon regeneration and is delivered via a non-surgical ultrasound guided injection. The firm has a Good Manufacturing Process (GMP) facility. The facility is licensed by the Therapeutic Goods Administration (TGA) for the manufacture of human tendon cells and cartilage cells for the regeneration of damaged tendon and cartilage.

OCC Intrinsic Value
1.89 AUD
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Orthocell Ltd's Capital Expenditures?
Capital Expenditures
-942k AUD

Based on the financial report for Jun 30, 2024, Orthocell Ltd's Capital Expenditures amounts to -942k AUD.

What is Orthocell Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-21%

Over the last year, the Capital Expenditures growth was -49%. The average annual Capital Expenditures growth rates for Orthocell Ltd have been -71% over the past three years , -21% over the past five years .

Back to Top